Island Pharmaceuticals to Highlight Antiviral Pipeline Advances at TechKnow Invest Roadshow in Melbourne and Sydney

Island Pharmaceuticals’ Dual-Asset Strategy in Antiviral Drug Development

Island Pharmaceuticals employs a dual development strategy focusing on two distinct antiviral candidates addressing different viral disease segments. The portfolio includes ISLA-101, with an established safety profile repurposed for prevention and treatment of dengue fever and other mosquito-borne or vector-transmitted diseases, and Galidesivir, a clinical-stage broad-spectrum antiviral. This diversified approach enables Island to target multiple high-priority disease areas simultaneously while mitigating development risks across its assets.

This strategy underscores Island’s dedication to addressing unmet medical needs where treatment options remain scarce. By advancing both a repurposed therapeutic with known safety and a novel broad-spectrum antiviral, the company aims to serve endemic disease markets and urgent biodefence demands. This combination offers potential revenue streams across diverse therapeutic areas and reflects a strategic allocation of development resources toward diseases with significant public health impact.

Galidesivir’s Broad-Spectrum Activity Against High-Priority Viral Threats

Galidesivir is Island’s lead clinical-stage candidate, exhibiting broad antiviral activity against more than 20 RNA viruses of concern. It has demonstrated efficacy against critical viral threats including Ebola, Marburg, Middle East Respiratory Syndrome (MERS), Zika, and Yellow fever. These viruses represent significant unmet medical needs, limited treatment options, and potential national security risks, positioning Galidesivir as a vital therapeutic in biodefence and public health.

The extensive antiviral spectrum of Galidesivir is especially valuable amid the unpredictable nature of emerging infectious diseases. Focusing on RNA viruses aligns with pathogens exhibiting pandemic potential and frequent inclusion in public health emergencies. Developing a molecule active against multiple high-threat pathogens enables Island to pursue regulatory pathways across several indications, potentially accelerating time to market and expanding commercial prospects. This strategic focus highlights the company’s understanding of both medical necessity and market dynamics in biodefence and emerging infectious disease sectors.

Progress on FDA Animal Rule Pathway for Marburg Virus Disease

Island is advancing Galidesivir under the FDA’s Animal Rule pathway specifically for Marburg Virus Disease treatment. This regulatory pathway allows FDA approval based on animal efficacy data when human trials are not ethical or feasible, applicable to rare and severe viral infections. Progression along this pathway marks a significant regulatory milestone, demonstrating FDA engagement and a clear development trajectory toward potential commercialisation.

Targeting Marburg Virus Disease reflects the infection’s severity and lack of approved treatments. Marburg is a rare, highly lethal filovirus with fatality rates exceeding 80% in some outbreaks, making it a prime candidate for accelerated regulatory review. FDA guidance on the Animal Rule pathway clarifies evidence and study design requirements, indicating Island’s development program aligns with regulatory expectations and reducing development risk for investors.

FDA-Directed Dose Optimisation Studies and Regulatory Engagement

Recent milestones include FDA-directed dose optimisation studies for Galidesivir, highlighting active regulatory collaboration and refinement of the development program. These studies aim to identify optimal dosing balancing efficacy and safety. FDA guidance on study parameters, timelines, and endpoints signifies the program is progressing along an established regulatory path with agency support.

Completion of dose optimisation studies is critical for regulatory submissions and influences approval timelines and commercial positioning. The FDA’s involvement underscores the importance of Galidesivir’s development and suggests the program meets scientific and regulatory standards. Investors may interpret this as a sign of regulatory backing and a structured path toward approval.

Ebola Preparedness Under WHO MEURI Framework

Island’s portfolio includes Ebola preparedness initiatives under the World Health Organization’s MEURI (Monitored Emergency Use of Unregistered and Investigational Therapies) framework. MEURI facilitates investigational therapeutic use during outbreaks when standard treatments are unavailable, relevant for viral haemorrhagic fevers like Ebola. Developing Galidesivir within this framework positions Island to contribute to outbreak responses while generating clinical data supporting future regulatory approval.

Participation in MEURI demonstrates Island’s commitment to real-world public health responsiveness and strengthens relationships with international health authorities and outbreak response organizations. Clinical data from outbreak settings, while not replacing traditional trials, provide valuable insights into drug performance. This involvement enhances Island’s reputation and stakeholder engagement beyond conventional pharmaceutical channels.

Commercial Potential in Biodefence and Emerging Infectious Disease Markets

Island’s strategic focus targets substantial commercial opportunities in both biodefence and emerging infectious disease sectors. The biodefence market is driven by government demand for medical countermeasures against biological threats, supported by dedicated budgets for developing and stockpiling therapeutics. Galidesivir’s activity against Ebola, Marburg, MERS, and other threats situates it well within this government procurement landscape, offering stable revenue potential less influenced by traditional market dynamics.

The emerging infectious disease market addresses newly identified or re-emerging viral pathogens causing public health emergencies with unpredictable demand spikes. Increasing spillover events and pandemic concerns have elevated investments in preparedness. Island’s broad-spectrum antiviral platform offers flexibility to target multiple pathogens, supporting a diversified commercial strategy. Combining biodefence contracts with outbreak response opportunities creates a more stable revenue model with attractive risk-adjusted returns for long-term investors focused on biodefence.

Investor Roadshow Presentation Details and Strategic Messaging

The TechKnow Invest Roadshow presentations on 27 July 2026 in Melbourne and 29 July 2026 in Sydney provide Island an opportunity to communicate recent achievements and future plans directly to investors. Non-executive chairman Jason Carroll will discuss company overview, regulatory and clinical progress, key milestones, and commercial positioning. This dual-city approach targets Australia’s primary financial hubs, enhancing investor accessibility.

Roadshows serve to clarify development timelines, address investor queries, build institutional support, and manage expectations. Highlighting FDA dose optimisation studies and the Animal Rule pathway signals tangible regulatory progress validating Island’s strategy. Covering regulatory and commercial topics comprehensively aims to instill investor confidence in both near-term milestones and long-term value creation. Presentation materials accompanying this update ensure transparency and wider investor access.

ISLA-101 Development for Dengue and Vector-Borne Diseases

ISLA-101 is Island’s second key asset, repurposed with an established safety profile for prevention and treatment of dengue fever, a mosquito-borne viral disease affecting 100-400 million people annually worldwide. This creates a significant market opportunity for prevention and treatment. The known safety profile may streamline development and regulatory approval, potentially accelerating commercialization compared to novel compounds.

Expanding ISLA-101’s application to other vector-borne diseases such as Zika, chikungunya, and yellow fever leverages its properties for a platform approach. These diseases present ongoing public health challenges and treatment gaps. Multi-indication development enhances revenue potential and return on investment. The growing transmission of vector-borne diseases due to climate change and expanding mosquito habitats further supports ISLA-101’s commercial relevance.

Global Regulatory Positioning and Market Reach

Island Pharmaceuticals, registered in Australia (ACN 641 183 842) with headquarters in Hawthorn East, Victoria, operates within the Australian regulatory framework and is listed on the ASX. Its development and regulatory efforts extend internationally, notably in the United States, where FDA involvement in Galidesivir’s development is prominent. This dual regulatory approach facilitates access to both Australian and globally recognized FDA approvals, enhancing market reach.

Engagement with international health bodies, including WHO through the MEURI framework, strengthens Island’s standing in global health security networks. This enhances credibility with international purchasers, public health agencies, and outbreak response organizations—key customers for biodefence therapeutics. For Australian investors, Island offers exposure to a company pursuing global health opportunities while maintaining governance under Australian regulations, exemplifying a growing model among Australian biotech firms addressing worldwide health needs.

Upcoming Milestones and Investor Focus Areas

Investors should closely monitor key upcoming developments including outcomes and timelines of FDA-directed dose optimisation studies, which are critical near-term milestones influencing regulatory and commercial pathways. Announcements regarding FDA meetings, especially concerning the Animal Rule pathway for Marburg or additional indications, will be material for assessing development progress and timelines. Updates on MEURI framework involvement in Ebola or other outbreak responses would validate Galidesivir’s clinical potential and provide real-world safety and efficacy data.

Longer-term catalysts include ISLA-101’s advancement through clinical phases targeting dengue and other vector-borne diseases, potentially expanding Island’s commercial footprint. Partnership, licensing, or development agreements with larger pharmaceutical companies or government agencies would be significant, potentially offering funding, resources, or commercialization avenues. Capital raising and funding announcements will remain relevant as clinical development requires substantial investment. Regulatory guidance and meeting disclosures will provide insight into FDA expectations and development probabilities, informing investor assessments.